![]() In the present study, we focused on proprioceptive processing. Treatments based on sensory-processing difficulties have led to inconclusive results (for meta-analyses, see ). Patients can exhibit distinct sensory processing subtypes associated with adaptive behaviors, as well as challenging behaviors (for a review, see ). ![]() These residual symptoms may be related to alterations in sensory processing, including changes in the integration of information across different sensory modalities (for reviews, see ). However, some patients may continue to suffer from residual behavioral disorders. In some resistant cases, clozapine, intensive behavioral interventions, electro-convulsive therapy (ECT), or an inpatient stay in a specialized unit using a systematic framework for exploration of comorbid conditions and a multidisciplinary care approach have also been recommended. Clinical trials have evaluated an array of therapeutic options providing clinicians with numerous off-label options. To date, only a few atypical antipsychotics have been approved to treat irritability and behavioral impairments associated with ASD or ID. Symptomatic treatments include behavioral and family interventions and psychotropic medications, mostly sedative drugs, mood stabilizers, and antipsychotics. In addition, subjects may experience intense pain from idiosyncratic sources but struggle to localize it and communicate it in an appropriate way, even if the physiological pain response is adequate. ![]() Many are caused by comorbid medical conditions, either organic or psychiatric. These behaviors often result in dramatic and even sometimes life-threatening conditions. The treatment of challenging behaviors (e.g., self-injurious behaviors, aggression, catatonia, and disruptive behaviors) in children and adolescents with severe autism spectrum disorder (ASD) and intellectual disability (ID) is a complex issue. (4) Conclusions: CGs appear to be a promising adjuvant treatment for both behavioral and postural impairments in individuals with autism and SPD. A comorbid GJH diagnosis was not associated with a better outcome. During the six-week duration, the treatment was generally well-tolerated. However, we did not observe a significant change in Dunn sensory scores. Motor performance was also significantly improved. Postural control in dorsal and profile positions was significantly improved between before and after wearing the CGs ( p = 0.006 and 0.007, respectively). (3) Results: We observed a significant effect on most ABC rating scores at two weeks, which persisted at six weeks (total score, p = 0.004 irritability, p = 0.007 hyperactivity, p = 0.001 lethargy, p = 0.001). We assessed challenging behaviors in these participants with the Aberrant Behavior Checklist (ABC), sensory integration with the Dunn questionnaire, and postural sway and motor performance using a self-designed motricity path at baseline, two weeks, and six weeks. Each patient received a CG to wear for at least 1 h (but most often longer) per day for six weeks. (2) Methods: We retrospectively described 14 patients with autism and SPD, including seven with comorbid GJH, who were hospitalized for major challenging behaviors with remaining behavioral symptomatology after the implementation of multidisciplinary approaches, including medication, treatment of organic comorbidities, and behavioral restructuring. ![]() We aimed to explore the use of CGs in individuals with autism and severe proprioceptive dysfunction (SPD), including individuals with GJH, to control posture and challenging behaviors. The effects of CGs are likely to be related to better proprioceptive control. (1) Background: Compression garments (CGs) are an adjuvant treatment for generalized joint hypermobility (GJH), including the Ehlers–Danlos syndrome/hypermobility types. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |